Health
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer – Small Caps
New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned phase 2 clinical trial on pancreatic…
New research describing the fundamental biology behind Amplia Therapeutics (ASX: ATX) planned phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a focal adhesion kinase (FAK) inhibitor prior to administering…
Continue Reading
-
Noosa News11 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News19 hours agoCountdown on for Noosa Eat & Drink Festival 2025
-
Noosa News16 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News18 hours agoThe Trailer for ‘The Bear’ Season Four Is Here — and It’s Cooking Up a Race to Keep Carmy and Syd’s Restaurant Running